52% Year-to-Date 2026 Revenue Growth
GRAND RAPIDS, Mich., Nov. 5, 2026 — Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter Financial Highlights
- Generated net revenue of $16.2 million in the third quarter, a 38% increase over the third quarter of 2025
- Achieved gross margin of 78.5% for the third quarter compared to 76.2% for the third quarter of 2025
- Increased average selling price of our implant systems to $7,616 in the third quarter, a 2% increase over the third quarter of 2025
- Increased full year 2026 net revenue guidance to $68 million to $70 million, representing growth of approximately 44% to 48% over full year 2025 net revenue
Recent Business Highlights
- Sold 2,126 total implant systems in the third quarter, an approximate 34% increase over the third quarter of 2025
- Completed the first surgical cases with InSet® Go, the company’s next-generation InSet® anatomic glenoid implant
- Received FDA 510(k) clearance for and initiated commercial launch of the N-22 humeral head, extending the company’s N-22 line for patients with metal hypersensitivity to anatomic procedures
- Announced exclusive partnership with ALM Ortho to develop additively manufactured solutions for severe deformity and complex revision cases
- Continued to expand the commercial leadership organization to support new territory expansion
- Promoted Jon Osborne to Chief Commercial Officer with responsibility for all elements of the company’s commercial organization
- Announced a settlement agreement with Catalyst OrthoScience Inc. to resolve all outstanding patent litigation between the two companies
“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving,” said Rob Ball, CEO of Shoulder Innovations. “This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”
Mr. Ball continued, “From a new product standpoint, we’re pleased to have recently completed the first successful cases with InSet Go, our next-generation glenoid implant. Beyond our own pipeline, our partners are extending what our platform can offer, with a new partnership bringing bespoke solutions for the most complex revision cases and our soft tissue relationship positioning us to serve more of each shoulder specialist’s practice. As we head into the final quarter of 2026, the commercial organization we’ve built continues to perform, our pipeline has never been deeper, and we look forward to finishing the year strong and building on that momentum into 2027, including the planned FDA submission of InSet Neo, our shoulder-specific robotic platform.”